Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2
1(100.0%)
1Total
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07291609Recruiting

Microplastics and Nanoplastics in Patients With Chronic Coronary Syndromes

Role: collaborator

NCT06965023Recruiting

Microplastics and Nanoplastics (MNPs) in Patients With ST-elevation Myocardial Infarction (STEMI)

Role: collaborator

NCT04303377Phase 2Withdrawn

Early Treatment With Evolocumab in Patients With ST-elevation Myocardial Infarction

Role: collaborator

NCT05261867Unknown

Cardioprotective Effect of SGLT2-I in Diabetic Patients With AMI (SGLT2-I AMI PROTECT Study)

Role: collaborator

NCT02998853Unknown

Non Culprit Functional Evaluation With 3D Angio QFR in STEMI PCI Procedure

Role: lead

All 5 trials loaded